Ideas Pursued.

Breakthroughs Delivered.

Focused Innovations for

Differentiated Parenterals

We develop high response differentiated injectables through our platform technology with a clear focus on ease-of-use and patient compliance


Diclofenac. Aceclofenac. Progesterone.

Etoricoxib, our breakthroughs in differentiated injectables.

Our R&D Team has a deep focus on innovations in injectables and has an array of first-in-the-market formulations, dosages and re-engineered delivery systems.


Concentrated R&D and in critical therapies

There is an utmost urgency for break-throughs in these therapies and our teams are steering differentiated injectables development to meet vital concerns.

Oncology. Pain Management. Critical Care. Anti Microbial / Anti Parasites


Progress Through Partnerships


Themis was founded as a joint venture with Gedeon Richter Ltd. Hungary, with a deep aptitude for partnerships. And a belief that answers have to be found together.

Leading the fight against disease in 64 countries

“Our vision is to develop targeted medicines that improve patient compliance and make healthcare far, far more effective.”

-Dr. Dinesh Patel, Ph.D, CEO

We are committed to being at the forefront in the movement against malaria. We have pledged our complete support to the government and other NGOs through contributions, formulations and people time

About Us

We want to take the world from pain to pain-free parentals through pain free work on dedicated innovations. Emal – the first in the world injectable against critical malaria, Etojet – the worlds first painless Etrocoxib injection and a first of its kinds injectable.
Diclofenac sodium for pain relief, are all a result of pursuit of ideas taken to their full potential. Our aim is to make disease management easier and painless for both patients and healthcare professionals.

Contact Us

11/12, Udyog Nagar,
S. V. Road, Goregaon (W),
Mumbai- 400104.

Phone: +91.22.67607080